Overview

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 mg.
Phase:
Phase 1
Details
Lead Sponsor:
The Medicines Company
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Oritavancin